DDInter1233 DDInter612
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duvelisib
Mitotane {u} (Compound) resembles {v} (Compound) Butoconazole
Butoconazole {u} (Compound) resembles {v} (Compound) Miconazole
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duvelisib
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
CYP11B1 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Mitotane {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Cilostazol
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Mitotane {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is downregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Mitotane (Compound) resembles Butoconazole (Compound) and Butoconazole (Compound) resembles Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Mitotane (Compound) binds CYP11B1 (Gene) and CYP11B1 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Mitotane (Compound) upregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Duvelisib
Mitotane (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Cilostazol (Compound) and Cilostazol may lead to a major life threatening interaction when taken with Duvelisib
Mitotane (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is downregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib